Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer im...
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Virus-neutralizing antibodies are a severe obstacle in oncolytic virotherapy. Here, we present a strategy to convert this unfavorable immune response into an anticancer immunotherapy via molecular retargeting. Application of a bifunctional adapter harboring a tumor-specific ligand and the adenovirus hexon domain DE1 for engaging antiadenoviral anti...
Alternative Titles
Full title
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5216df34738f45e49e9168b8b9041417
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5216df34738f45e49e9168b8b9041417
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-019-11137-5
